Repligen Corporation Company Profile (NASDAQ:RGEN)

About Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGEN
  • CUSIP: 75991610
  • Web:
  • Market Cap: $1.26473 billion
  • Outstanding Shares: 37,356,000
Average Prices:
  • 50 Day Moving Avg: $40.45
  • 200 Day Moving Avg: $39.77
  • 52 Week Range: $26.16 - $46.81
  • Trailing P/E Ratio: 74.21
  • Foreward P/E Ratio: 51.24
  • P/E Growth: 2.59
Sales & Book Value:
  • Annual Revenue: $113.32 million
  • Price / Sales: 12.50
  • Book Value: $5.60 per share
  • Price / Book: 6.77
  • EBITDA: $29.54 million
  • Net Margins: 15.61%
  • Return on Equity: 9.90%
  • Return on Assets: 5.93%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 11.87%
  • Quick Ratio: 10.29%
  • Average Volume: 377,043 shs.
  • Beta: 1.18
  • Short Ratio: 11.59

Frequently Asked Questions for Repligen Corporation (NASDAQ:RGEN)

What is Repligen Corporation's stock symbol?

Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen Corporation's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) released its quarterly earnings data on Thursday, August, 3rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.05. The business earned $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation's revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.16 EPS. View Repligen Corporation's Earnings History.

When will Repligen Corporation make its next earnings announcement?

Repligen Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Repligen Corporation.

What guidance has Repligen Corporation issued on next quarter's earnings?

Repligen Corporation issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $0.57-0.62 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $138-144 million, compared to the consensus revenue estimate of $128.09 million.

Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?

4 brokerages have issued 12-month target prices for Repligen Corporation's stock. Their forecasts range from $40.00 to $50.00. On average, they anticipate Repligen Corporation's share price to reach $46.00 in the next twelve months. View Analyst Ratings for Repligen Corporation.

Who are some of Repligen Corporation's key competitors?

Who are Repligen Corporation's key executives?

Repligen Corporation's management team includes the folowing people:

  • Karen A. Dawes, Independent Chairperson of the Board
  • Tony John Hunt, President, Chief Executive Officer, Director
  • Jon K. Snodgres, Chief Financial Officer
  • Howard Benjamin Ph.D., Vice President - Business Development
  • Nicolas M. Barthelemy, Independent Director
  • Glenn L. Cooper M.D., Independent Director
  • John G. Cox, Independent Director
  • Glenn P. Muir, Independent Director
  • Thomas F. Ryan Jr., Independent Director

Who owns Repligen Corporation stock?

Repligen Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include EDDLEMAN ROY T (11.00%) and Assenagon Asset Management S.A. (0.21%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen Corporation.

Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?

Repligen Corporation's stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Repligen Corporation.

How do I buy Repligen Corporation stock?

Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen Corporation's stock price today?

One share of Repligen Corporation stock can currently be purchased for approximately $37.92.

MarketBeat Community Rating for Repligen Corporation (NASDAQ RGEN)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Repligen Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Repligen Corporation (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $46.00 (21.31% upside)
Consensus Price Target History for Repligen Corporation (NASDAQ:RGEN)
Price Target History for Repligen Corporation (NASDAQ:RGEN)
Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Jefferies Group LLCReiterated RatingHold$40.00N/AView Rating Details
10/2/2017First AnalysisUpgradeEqual Weight -> Overweight$47.00MediumView Rating Details
9/26/2017StephensReiterated RatingOverweight$50.00HighView Rating Details
7/21/2017William BlairInitiated CoverageOutperform -> OutperformLowView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 -> $47.00HighView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Repligen Corporation (NASDAQ:RGEN)
Earnings by Quarter for Repligen Corporation (NASDAQ:RGEN)
Earnings History by Quarter for Repligen Corporation (NASDAQ RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.11N/AView Earnings Details
8/3/2017Q2 2017$0.15$0.20$31.72 million$32.40 millionViewListenView Earnings Details
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.55
2018 EPS Consensus Estimate: $0.73
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20174$0.09$0.15$0.13
Q4 20173$0.12$0.16$0.14
Q1 20183$0.14$0.19$0.17
Q2 20183$0.18$0.24$0.20
Q3 20182$0.17$0.18$0.18
Q4 20182$0.18$0.19$0.19
(Data provided by Zacks Investment Research)


Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Repligen Corporation (NASDAQ:RGEN)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 96.45%
Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)
Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Repligen Corporation (NASDAQ:RGEN)
Latest Headlines for Repligen Corporation (NASDAQ:RGEN)
DateHeadline logoRGEN Crosses Above Key Moving Average Level - October 20 at 3:58 PM logoETFs with exposure to Repligen Corp. : October 20, 2017 - October 20 at 3:57 PM logoRepligen Corporation (RGEN) Given Consensus Rating of "Buy" by Brokerages - October 19 at 2:34 AM logoContrasting Advanced Accelerator Applications (AAAP) and Repligen Corporation (RGEN) - October 18 at 4:24 PM logoCritical Survey: Repligen Corporation (RGEN) versus TherapeuticsMD (TXMD) - October 15 at 9:00 AM logoFinancial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN) - October 12 at 4:24 PM logoRepligen Corporation (RGEN) Cut to "Hold" at Zacks Investment Research - October 11 at 10:18 AM logoHead to Head Review: Advanced Accelerator Applications (AAAP) & Repligen Corporation (RGEN) - October 11 at 12:30 AM logoETFs with exposure to Repligen Corp. : October 9, 2017 - October 10 at 6:23 AM logoRepligen Corporation (RGEN) versus Its Peers Head-To-Head Review - October 9 at 4:12 PM logoRepligen Corporation (RGEN) Upgraded to Buy at Zacks Investment Research - October 8 at 11:40 AM logoCritical Contrast: Assembly Biosciences (ASMB) & Repligen Corporation (RGEN) - October 8 at 10:38 AM logo$0.11 EPS Expected for Repligen Corporation (RGEN) This Quarter - October 8 at 12:20 AM logoRepligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group Forecasts - October 4 at 4:50 PM logoRockwell Medical (RMTI) vs. Repligen Corporation (RGEN) Head-To-Head Analysis - September 28 at 8:30 PM logoRelative Strength Alert For Repligen - Nasdaq - September 27 at 11:15 PM logoNotable Two Hundred Day Moving Average Cross - RGEN - September 27 at 6:13 PM logoRepligen Corp. (RGEN) Tumbled To Over A 4-Month Low - September 27 at 6:13 PM logoBrokers Set Expectations for Repligen Corporation's Q2 2018 Earnings (RGEN) - September 27 at 12:44 PM logoRepligen Corporation (RGEN) Stock Rating Reaffirmed by Stephens - September 26 at 7:34 PM logoMid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge - September 26 at 3:28 PM logoWilliam Blair Comments on Repligen Corporation's Q1 2018 Earnings (RGEN) - September 26 at 10:26 AM logoRepligen continues slide ahead of Investor Day; shares down 11% in a week - September 26 at 9:55 AM logoRepligen Corporation (RGEN) & Supernus Pharmaceuticals (SUPN) Head to Head Analysis - September 24 at 6:18 PM logoRepligen Corporation (RGEN) Receives Consensus Rating of "Buy" from Brokerages - September 24 at 2:56 AM logoRepligen Corporation (RGEN) vs. Its Peers Head to Head Contrast - September 17 at 10:32 PM logoRepligen Announces Analyst Day and Webcast - GlobeNewswire (press release) - September 17 at 7:22 AM logoRepligen Announces Analyst Day and Webcast - September 15 at 8:14 AM logoRepligen Corporation (RGEN) Stock Rating Reaffirmed by Jefferies Group LLC - September 14 at 7:16 PM logoRepligen Corporation (RGEN) & Aimmune Therapeutics (AIMT) Head-To-Head Contrast - September 13 at 12:38 AM logoRepligen Corporation (RGEN) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 9 at 7:56 AM logoHave Investors Already Priced In Repligen Corporation’s (RGEN) Growth? - September 9 at 7:56 AM logoRepligen Corporation (RGEN) Expected to Post Quarterly Sales of $36.36 Million - September 2 at 4:58 AM logoRepligen to Present at Baird's 2017 Global Healthcare Conference - GlobeNewswire (press release) - August 31 at 9:25 AM logoRepligen to Present at Baird’s 2017 Global Healthcare Conference - August 31 at 9:25 AM logoRepligen Corporation (RGEN) Given Consensus Recommendation of "Buy" by Brokerages - August 30 at 2:56 AM logoFinancial Analysis: Supernus Pharmaceuticals (SUPN) and Repligen Corporation (RGEN) - August 26 at 10:06 PM logoRepligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : August 25, 2017 - August 25 at 10:53 AM logoRepligen Corporation (RGEN) Raised to B- at TheStreet - August 15 at 8:34 PM logo Brokerages Anticipate Repligen Corporation (RGEN) Will Announce Quarterly Sales of $34.66 Million - August 15 at 11:55 AM logoSee what the IHS Markit Score report has to say about Repligen Corp. - August 15 at 6:43 AM logoRepligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : August 14, 2017 - August 15 at 6:43 AM logoRepligen Corp. – Value Analysis (NASDAQ:RGEN) : August 14, 2017 - August 15 at 6:43 AM logo$0.12 EPS Expected for Repligen Corporation (NASDAQ:RGEN) This Quarter - August 13 at 8:56 AM logoFY2017 EPS Estimates for Repligen Corporation Increased by Analyst (NASDAQ:RGEN) - August 11 at 10:45 AM logoRepligen Corporation Expected to Post FY2020 Earnings of $1.08 Per Share (NASDAQ:RGEN) - August 10 at 1:50 PM logoFirst Analysis Brokers Reduce Earnings Estimates for Repligen Corporation (NASDAQ:RGEN) - August 10 at 9:20 AM logoQ3 2017 EPS Estimates for Repligen Corporation (RGEN) Reduced by Analyst - August 9 at 7:28 AM logoAbbVie (ABBV) versus Repligen Corporation (NASDAQ:RGEN) Critical Survey - August 7 at 9:08 AM logoQ3 2017 EPS Estimates for Repligen Corporation (NASDAQ:RGEN) Lifted by Analyst - August 7 at 7:34 AM



Repligen Corporation (RGEN) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.